Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares were up 11.9% on Tuesday . The company traded as high as $1.67 and last traded at $1.60. Approximately 55,221 shares changed hands during trading, an increase of 2,451% from the average daily volume of 2,165 shares. The stock had previously closed at $1.43.
Graybug Vision Price Performance
The stock’s 50 day moving average is $1.73 and its 200-day moving average is $2.18. The company has a market capitalization of $2.51 million, a P/E ratio of -0.92 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Breakout Alert: Disney Stock Hits Multi-Year High
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Forget IBM: Accenture’s AI Momentum Is Your Next Buy
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
